Suba E J, Nguyen C H, Nguyen B D, Raab S S
Kaiser Permanente Medical Center, Redwood City, California, USA.
Cancer. 2001 Mar 1;91(5):928-39.
Cervical carcinoma is the leading cause of cancer-related death among women in the developing world. The absence of cervical screening in Vietnam and other developing countries is due in large part to the perceived expense of implementing Papanicolaou cytology screening services, although, to the authors' knowledge, the cost-effectiveness of establishing such services has never been studied in a developing country.
Using decision analytic methods, the authors assessed cost-effectiveness of Pap screening from a societal perspective in Vietnam, the world's 9th most populous developing country (estimated 1999 population, 79 million). Outcomes measured included life expectancy, cervical carcinoma incidence, cost per woman, and cost-effectiveness.
Total costs to establish a nationwide 5-year interval Pap screening program in Vietnam will average less than $148,400 annually during the 10-year time period assumed necessary to develop the program and may be considerably lower if only high risk geographic areas are targeted. Maintenance costs will average less than $0.092 annually per woman in the target screening population. Assuming 70% program participation, cervical carcinoma incidence will decrease from 26 in 100,000 to 14.8 in 100,000, and cost-effectiveness will be $725 per discounted life-year. Several assumptions used in this analysis constitute biases against the effectiveness of Pap screening, which in reality may be significantly more cost-effective than reported here.
Contrary to widespread belief, Pap screening in developing countries such as Vietnam is extraordinarily inexpensive and appears to be cost-effective. Because prospects are uncertain regarding useful alternatives to the Pap test, the evidence-based argument for establishing conventional Pap screening services in developing countries such as Vietnam is compelling. Population-based conventional Pap screening services have been established de novo in Vietnam and are now operational.
在发展中国家,宫颈癌是女性癌症相关死亡的主要原因。越南和其他发展中国家未开展宫颈筛查,很大程度上是因为人们认为实施巴氏细胞学筛查服务费用高昂,不过据作者所知,在发展中国家尚未对建立此类服务的成本效益进行过研究。
作者采用决策分析方法,从越南社会角度评估巴氏筛查的成本效益。越南是世界上人口第九多的发展中国家(1999年估计人口为7900万)。所测量的结果包括预期寿命、宫颈癌发病率、每位女性的成本以及成本效益。
在越南建立一个为期5年的全国性巴氏筛查项目,在假设开展该项目所需的10年时间内,每年总成本平均将低于148,400美元,如果仅针对高风险地理区域,成本可能会低得多。目标筛查人群中每位女性的维护成本每年平均将低于0.092美元。假设项目参与率为70%,宫颈癌发病率将从每10万人中的26例降至每10万人中的14.8例,成本效益将为每贴现生命年725美元。本分析中使用的几个假设对巴氏筛查的有效性构成了偏差,实际上其成本效益可能比此处报告的要高得多。
与普遍看法相反,在越南等发展中国家,巴氏筛查成本极低,而且似乎具有成本效益。由于巴氏试验的有用替代方法前景不明,在越南等发展中国家建立传统巴氏筛查服务的循证论据很有说服力。越南已全新建立了基于人群的传统巴氏筛查服务,目前已投入运营。